结肠炎
失调
炎症性肠病
胃肠道
肠道菌群
炎症
微生物群
益生菌
免疫学
医学
内科学
生物信息学
生物
疾病
遗传学
细菌
作者
Mei Yang,Honglan Shen,Suting Zhong,Zongpu Xu,Xiangyu Liu,Weicheng Wu,Chuanbin Mao,Mingying Yang
出处
期刊:Aggregate
[Wiley]
日期:2024-03-06
卷期号:5 (4)
被引量:1
摘要
Abstract Anti‐inflammatory compounds, delivered as a payload to the gastrointestinal tract (GIT) by carriers, still cannot treat inflammatory bowel diseases without avoiding side effects. Here, we developed payload‐free protein nanoparticles (PNPs) that crossed GIT to retain in the colon and treat colitis by restoring intestinal barrier integrity by modulating gut microbiome and metabolome. Specifically, PNPs, orally administered to mice with acute colitis, reached the colon within three hours. Consequently, PNPs improve gut microbiota dysbiosis to reverse metabolism balance, suppressing the expression of tumor‐necrosis factor α and toll‐like receptor 4 that restores the intestinal barrier integrity. PNPs then ameliorated colon inflammation and attenuated gut microbiota dysbiosis by exerting probiotic effects on gut microbiota, treating colitis in a week more effectively than the clinically often used 5‐aminosalicylic acid without causing undesired side effects. Such PNPs represent safe, sustainable, and cost‐effective therapeutics for treating inflammatory and metabolic diseases by eliminating microbial and metabolomic imbalance.
科研通智能强力驱动
Strongly Powered by AbleSci AI